Sale
New

NextSeq 550Dx Sequencing System from Illumina

Name: NextSeq 550Dx Sequencing System from Illumina
SKU: NextSeq 550Dx

Bio Rad C1000 Touch PCR Thermocycler

ResMed AirMini AutoSet Travel CPAP

Reviews (0) Add a review

$39,199.30 $55,999.00

Tax shipping

No tax

Experience the precision of Illumina's NextSeq 550Dx Sequencing System: designed for diagnostic-grade applications with unparalleled sequencing depth and throughput. Ideal for clinical research and in-depth genomic investigations. Explore its state-of-the-art capabilities

All payments are Protected. Your data are secure
Free Worldwide Shipping for order over $300
30-Day Warranty and get all your money back.

The NextSeq 550Dx instrument is FDA regulated and CE-in vitro diagnostic (IVD) marked, enabling clinical laboratories to develop and perform a wide range of applications, from NGS IVD assays using targeted panels, to clinical research applications that include methods from targeted panels to whole genomes.

The NextSeq 550Dx instrument is the first high-throughput FDAregulated and CE-marked platform to deliver the power of nextgeneration sequencing (NGS) to the clinical laboratory.

"Great mid-range sequencer. Not cheapest but great for small to medium sequencing core facilities. Very reliable and easy to use. Also modified library preps reduce library costs too... these were the workhorse for sequencing 80,000 COVID genomes over 2 years in our lab supporting the surveillance of new variants."

David Baker - Quadram

Key Features:

Reproductive health testing

Explore solutions for expecting parents, noninvasive prenatal testing (NIPT), chromosomal analysis for preimplantation genetic screening (PGS), and genetic testing for rare diseases with the NextSeq 550Dx instrument.

Oncology testing

NGS is transforming oncology by offering a more comprehensive and deeper understanding of cancers and tumors. See how to deliver accurate, sensitive, and fast results with the NextSeq 550Dx for oncology testing.

IVD assay development

Customize your NGS-based IVD assays for analysis on the NextSeq 550Dx instrument platform. We’re even collaborating with diagnostic technology partners to expand our menu of clinical assays to help pave the way for more accurate diagnosis, prognosis, and therapeutic options.

For In Vitro Diagnostic Use. Contact an Illumina representative for regional availably.

Flexibility of dual operating modes

Work within a regulated sequencing workflow for developing current and future NGS IVD tests in the pipeline, while retaining the flexibility to work in a research environment and use the full range of Illumina sequencing methods for a wide range of applications.

Consistency of a Clinical Instrument

The instrument and sequencing reagents are all regulated by the FDA, developed under design control principles, manufactured under Current Good Manufacturing Practices (cGMPs), and verified for consistent assay performance.

Design Your Own NGS Assays for Use on the NextSeq 550Dx System

Paired with the TruSeq Custom Amplicon Kit Dx library preparation kit and the NextSeq 550Dx Reagent Kit, the NextSeq 550Dx is part of an IVD development toolkit that enables clinical labs to design clinical assays with regulated components*.

This instrument includes a Diagnostic Mode and a Research Mode, which provides the flexibility to perform IVD testing, LDT development, and clinical research on a single platform. For large clinical laboratories, the NextSeq 550Dx instrument offers a validated high-throughput platform and provides access to an ever-expanding pipeline of clinical applications in the fields of oncology. NextSeq 550Dx instrument can generate more than 90 Gb of data in less than two days, delivers the consistency of a regulated platform and includes robustness improvements in software and instrument design. In addition, running in Research Mode supports all currently available research applications including exome sequencing, transcriptome profiling, customer designed targeted panels, and microarray scanning.

While the NextSeq 550Dx instrument can generate more than 90 Gb of data in less than two days, it also delivers the consistency of a regulated platform and includes robustness improvements in software and instrument design. In addition, running in Research Mode supports all currently available research applications including exome sequencing, transcriptome profiling, customerdesigned targeted panels, and microarray scanning.

With the NextSeq 550Dx instrument, clinical laboratories can run in regulated Dx Mode for IVD/LDT testing or run in Research Mode to accelerate clinical studies without sacrificing the speed and power of a high-throughput sequencer.

General Specification

The amount of data obtained

≥ 90 Gb*

*data obtained from sequencing of the PhiX Control library

Single readings in one operating mode

≥ 300 mln

Maximum length of readings

2 × 150 bp

Read Length	2 × 150 bp
Output	≥ 90 Gb
Total Time*	≤ 35 hours
Throughput	8–96 samples/run depending on assay

* Includes cluster generation, 2 × 150 bp dual-indexed sequencing, reagent purge, and post-run wash.

High-Output	≥ 600 M paired-end reads

Bases with ≥ Q30	> 75%

Total Overall Accuracy – Somatic Variant Caller	≥ 99.98%†
Total Overall Accuracy – Germline Variant Caller	≥ 99.99%†

† Using a representative assay designed to query a variety of genes covering approximately 13,000 bases across 23 different chromosomes, and containing wide GC content (18% to 87%), indels (up to 25 base pairs), and homopolymers (7 to 13 nucleotides).

Power Requirements	100–240 Volts AC @ 50/60 Hz, 600w max
RFID Radio Frequency	13.56 MHz
RFID Power	200 mW
LED	Green 510-525 nm, Red 645-655 nm; Laser diode: 780 nm, Class IIIb
Laser	Class 1 laser product embedded with a Class 3B diode

Temperature	Transportation and Storage: -10°C to 50°C. Operating Conditions: Maintain a lab temperature of 19°C to 25°C (22°C±3°C).
RFID Radio Frequency	13.56 MHz